Newsroom: In the News

Drug Discovery World published an editorial feature in which Elke Bestel, Chief Medical Officer at Igyxos, discusses the current treatment landscape for infertility and the biological factors contributing to both male and female infertility.

​

The article outlines the limitations of existing treatment options, including the absence of broadly approved therapies for male infertility, and describes how IGX12, a monoclonal antibody designed to enhance follicle-stimulating hormone (FSH) activity, could represent a differentiated approach for treating infertility in both men and women.

 

Read the full article in Drug Discovery World (page 36) via free sign-up